Timothy C. Dec
CIK: 0001194020
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
SUPERNUS PHARMACEUTICALS, INC.
Discretionary Trading P&L
Holdings
Transaction History (42 total)
- Oct 30, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Award(A)DirectRestricted Stock Unit
70K shares- - Aug 12, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Tax Payment(F)Direct604 shares at avg. $46.57$28K - Aug 12, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Exercise(M)Direct1.3K shares- - Jul 29, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Award(A)DirectPerformance Share Unit
1.3K shares- - Mar 6, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Tax Payment(F)Direct1.5K shares at avg. $54.73$79K - Mar 6, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Exercise(M)Direct3K shares- - Mar 6, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Tax Payment(F)Direct1.4K shares at avg. $54.73$78K - Mar 6, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Exercise(M)Direct3K shares- - Feb 28, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Award(A)DirectPerformance Share Unit
3K shares- - Feb 28, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Award(A)DirectPerformance Share Unit
3K shares- - Feb 25, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Tax Payment(F)Direct1.3K shares at avg. $50.69$65K - Feb 25, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Disposition(D)DirectRestricted Stock Unit
2.5K shares- - Feb 25, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Award(A)Direct2.5K shares- - Feb 24, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Award(A)Direct3K shares- - Feb 24, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Award(A)Direct1.1K shares- - Feb 24, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Tax Payment(F)Direct603 shares at avg. $51.35$31K - Feb 24, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Award(A)Direct500 shares- - Feb 24, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Tax Payment(F)Direct242 shares at avg. $50.86$12K - Feb 24, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Tax Payment(F)Direct1.5K shares at avg. $50.86$78K - Feb 24, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Disposition(D)DirectRestricted Stock Unit
1.1K shares- - Feb 24, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Disposition(D)DirectRestricted Stock Unit
500 shares- - Feb 24, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Disposition(D)DirectRestricted Stock Unit
3K shares- - Feb 18, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Award(A)DirectEmployee Stock Option (Right to Buy)
17.5K shares- - Feb 18, 2026SUPN
SUPERNUS PHARMACEUTICALS, INC.
Award(A)DirectRestricted Stock Unit
3K shares- - Aug 22, 2025SUPN
SUPERNUS PHARMACEUTICALS, INC.
Sale(S)Direct11.8K shares at avg. $44.49$524K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 30, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Award(A) Restricted Stock Unit | 70,000 | - | - | Direct |
| Aug 12, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Tax Payment(F) | 604 | $46.57 | $28,128 | Direct |
| Aug 12, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Exercise(M) | 1,250 | - | $0 | Direct |
| Jul 29, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Award(A) Performance Share Unit | 1,250 | - | - | Direct |
| Mar 6, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Tax Payment(F) | 1,450 | $54.73 | $79,359 | Direct |
| Mar 6, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Exercise(M) | 3,000 | - | $0 | Direct |
| Mar 6, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Tax Payment(F) | 1,433 | $54.73 | $78,428 | Direct |
| Mar 6, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Exercise(M) | 3,000 | - | $0 | Direct |
| Feb 28, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Award(A) Performance Share Unit | 3,000 | - | - | Direct |
| Feb 28, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Award(A) Performance Share Unit | 3,000 | - | - | Direct |
| Feb 25, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Tax Payment(F) | 1,279 | $50.69 | $64,833 | Direct |
| Feb 25, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Disposition(D) Restricted Stock Unit | 2,500 | - | - | Direct |
| Feb 25, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Award(A) | 2,500 | - | $0 | Direct |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Award(A) | 3,000 | - | $0 | Direct |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Award(A) | 1,125 | - | $0 | Direct |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Tax Payment(F) | 603 | $51.35 | $30,964 | Direct |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Award(A) | 500 | - | $0 | Direct |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Tax Payment(F) | 242 | $50.86 | $12,308 | Direct |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Tax Payment(F) | 1,524 | $50.86 | $77,511 | Direct |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Disposition(D) Restricted Stock Unit | 1,125 | - | - | Direct |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Disposition(D) Restricted Stock Unit | 500 | - | - | Direct |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Disposition(D) Restricted Stock Unit | 3,000 | - | - | Direct |
| Feb 18, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Award(A) Employee Stock Option (Right to Buy) | 17,500 | - | - | Direct |
| Feb 18, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Award(A) Restricted Stock Unit | 3,000 | - | - | Direct |
| Aug 22, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | Sale(S) | 11,780 | $44.49 | $524,092 | Direct |
1-25 of 42 transactions
About DEC TIMOTHY C
DEC TIMOTHY C (SEC CIK 0001194020) files insider reports with the SEC as Senior Vice-President & CFO of SUPERNUS PHARMACEUTICALS, INC. (SUPN).
Signal8 holds 14 ownership filings by DEC TIMOTHY C, all Form 4s, filed between Feb 21, 2025 and Nov 2, 2026. Those filings report 42 transactions, from Feb 19, 2025 to Oct 30, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on DEC TIMOTHY C's filings is in ROCKVILLE, MD.
Recent filings by DEC TIMOTHY C
- Oct 30, 2026: Grant or award of SUPN derivative securities (Form 4, code A).
- Aug 12, 2026: Tax withholding of SUPN shares (Form 4, code F).
- Aug 12, 2026: Option exercise of SUPN shares (Form 4, code M).
- Jul 29, 2026: Grant or award of SUPN derivative securities (Form 4, code A).
- Mar 6, 2026: Tax withholding of SUPN shares (Form 4, code F).
Other insiders filing for SUPERNUS PHARMACEUTICALS, INC. (SUPN)
- Khattar Jack A., President, CEO
- Rubin Jonathan, SVP, Chief Medical Officer
- Mottola Frank, SVP, Chief Tech. Ops. Officer
- Horich William Todd, SVP, Commercial Operations
- Bhatt Padmanabh P., Sr. VP of IP, CSO
- Hudson Frederick M., Director